A Decision Chart for Assessing and Improving the Transferability of Economic Evaluation Results Between Countries
暂无分享,去创建一个
Reiner Leidl | Talitha Feenstra | T. Feenstra | R. Leidl | R. Welte | Robert Welte | Hans Jager | H. Jager
[1] R. Baltussen,et al. The impact of age on cost-effectiveness ratios and its control in decision making. , 1996, Health economics.
[2] G. Stoddart,et al. A re-examination of the meaning and importance of supplier-induced demand. , 1994, Journal of health economics.
[3] Gillian D. Sanders,et al. Cost Effectiveness of a Potential Vaccine for Human papillomavirus , 2003, Emerging infectious diseases.
[4] B. Hylander,et al. An international study of patient compliance with hemodialysis. , 1999, JAMA.
[5] Muammar Qaddafi,et al. The Green Book , 1975 .
[6] A Gafni,et al. Economic evaluations in the critical care literature: do they help us improve the efficiency of our unit? , 1996, Critical care medicine.
[7] R. Panerai,et al. Transferability of Health Technology Assessment with Particular Emphasis on Developing Coutries , 1988, International Journal of Technology Assessment in Health Care.
[8] Charles E. Phelps,et al. Good Technologies Gone Bad , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.
[9] Jacobs-van der Bruggen Mam,et al. Aan roken toe te schrijven productiviteitskosten voor Nederlandse werkgevers in 1999 , 2002 .
[10] A. Enthoven,et al. Should operations be regionalized? The empirical relation between surgical volume and mortality. , 1980, The New England journal of medicine.
[11] F. Rutten,et al. Economic evaluation and health care decision-making. , 1996, Health policy.
[12] S. Yusuf. Variations between countries in invasive cardiac procedures , 1998, The Lancet.
[13] L. Goldman,et al. Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease. Use of a decision-analytic model. , 1994, Circulation.
[14] J. Caro,et al. Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium. The WOSCOPS Economic Analysis Group. West of Scotland Coronary Prevention Study. , 2000, Acta cardiologica.
[15] R. Willke,et al. Economic Analysis of Tirilazad Mesylate for Aneurysmal Subarachnoid Hemorrhage: Economic Evaluation of a Phase III Clinical Trial in Europe and Australia , 1998, International Journal of Technology Assessment in Health Care.
[16] R. Baltussen,et al. Making cost assessments based on RCTs more useful to decision-makers. , 1996, Health policy.
[17] K. Schulman,et al. Differences in care-seeking behavior for acute chest pain in the United States and Japan. , 2004, American heart journal.
[18] C. Wolfe,et al. A COMPARISON OF THE COST-EFFECTIVENESS OF STROKE CARE PROVIDED IN LONDON AND COPENHAGEN , 2000, International Journal of Technology Assessment in Health Care.
[19] S. Reske,et al. Primary staging of lymphomas: cost-effectiveness of FDG-PET versus computed tomography , 2000, European Journal of Nuclear Medicine.
[20] Nazmi Sari,et al. Do competition and managed care improve quality? , 2002, Health economics.
[21] Antonio Colombo,et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II) , 1998, The Lancet.
[22] D. Elliott. Costing intensive care services: a review of study methods, results and limitations. , 1997, Australian critical care : official journal of the Confederation of Australian Critical Care Nurses.
[23] H S Luft,et al. Effects of Surgeon Volume and Hospital Volume on Quality of Care in Hospitals , 1987, Medical care.
[24] P Carlsson,et al. Resource costing for multinational neurologic clinical trials: methods and results. , 1998, Health economics.
[25] M A Koopmanschap,et al. Analysis of costs and cost-effectiveness in multinational trials. , 2001, Health policy.
[26] A. Tonkin. Issues in extrapolating from clinical trials to clinical practice and outcomes. , 1998, Australian and New Zealand journal of medicine.
[27] A. Haycox,et al. Customising an International Disease Management Model to the Needs of Individual Countries , 2012, PharmacoEconomics (Auckland).
[28] R. Leidl. Some Factors to Consider when Using the Results of Economic Evaluation Studies at the Population Level , 1994, International Journal of Technology Assessment in Health Care.
[29] R. Brooks,et al. EuroQol: health-related quality of life measurement. Results of the Swedish questionnaire exercise. , 1991, Health policy.
[30] R. Willke,et al. Estimating country-specific cost-effectiveness from multinational clinical trials. , 1998, Health economics.
[31] M F Drummond,et al. Economic Analysis Alongside Clinical Trials: Revisiting the Methodological Issues , 1991, International Journal of Technology Assessment in Health Care.
[32] M. Dougados,et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries , 2002, Annals of the rheumatic diseases.
[33] W. Edmunds,et al. Economic Evaluation of Vaccination Programs: The Impact of Herd-Immunity , 2003, Medical decision making : an international journal of the Society for Medical Decision Making.
[34] Daniel Polsky,et al. Design and analysis of unit cost estimation studies: How many hospital diagnoses? How many countries? , 2003, Health economics.
[35] Timing of adoption of laparoscopic cholecystectomy in Denmark and in The Netherlands: a comparative study. , 2001, Health policy.
[36] M. Koopmanschap,et al. A Practical Guide for Calculating Indirect Costs of Disease , 1996, PharmacoEconomics.
[37] Regina E. Herzlinger,et al. Market Driven Health Care: Who Wins, Who Loses in the Transformation of America's Largest Service Industry , 1996 .
[38] N. Ikegami,et al. Estimating an EQ-5D population value set: the case of Japan. , 2002, Health economics.
[39] Banz,et al. New Perspectives on the Cost-Effectiveness of Palmaz-Schatzª Coronary Stenting, Balloon Angioplasty, and Coronary Artery Bypass Surgery. , 1997, The Journal of invasive cardiology.
[40] B. O'brien,et al. A tale of two (or more) cities: geographic transferability of pharmacoeconomic data. , 1997, The American journal of managed care.
[41] V. Ho. Learning and the evolution of medical technologies: the diffusion of coronary angioplasty. , 2002, Journal of health economics.
[42] Banz,et al. Cost-Effectiveness of Palmaz-Schatzª Stenting in Patients with Coronary Artery Disease in Germany. , 1997, The Journal of invasive cardiology.
[43] M. R. Mölken,et al. Cost-Effectiveness Analysis of Formoterol Versus Salmeterol in Patients with Asthma , 1998, PharmacoEconomics.
[44] W. Stason. Cost-Effectiveness Analysis in Health Care: Opportunities and Challenges to International Comparisons , 1990 .
[45] M. Drummond,et al. Issues in the Cross-National Assessment of Health Technology , 1992, International Journal of Technology Assessment in Health Care.
[46] W. Greiner,et al. The transferability of international economic health-economic results to national study questions , 2000, HEPAC Health Economics in Prevention and Care.
[47] P. Danzon,et al. Cross-national price differences for pharmaceuticals: how large, and why? , 2000, Journal of health economics.
[48] T. Weiss,et al. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? , 2001, Diabetes care.
[49] A. Mason,et al. The Generalisability of Pharmacoeconomic Studies , 2012, PharmacoEconomics.
[50] W. Greiner,et al. Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation , 2009, Medizinische Klinik.
[51] R. Lawrence,et al. COMMITTEE TO STUDY PRIORITIES FOR VACCINE DEVELOPMENT , 2000 .
[52] P. Pattynama,et al. International differences in health care costs in Europe and the United States: Do these affect the cost-effectiveness of diagnostic strategies for pulmonary embolism? , 1999, European Radiology.
[53] M. Drummond,et al. Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .
[54] D Menon,et al. Canadian Coordinating Office for Health Technology Assessment. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[55] P. Macfarlane,et al. West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996 .
[56] Andrew H. Briggs,et al. Handling Uncertainty in Cost-Effectiveness Models , 2000, PharmacoEconomics.
[57] E. Topol,et al. In-hospital costs associated with new percutaneous coronary devices. , 1991, The American journal of cardiology.
[58] B. O'brien,et al. Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials? , 1996, Medical care.
[59] ANALYZING DIFFERENCES IN THE COSTS OF TREATMENT ACROSS CENTERS WITHIN ECONOMIC EVALUATIONS , 2001, International Journal of Technology Assessment in Health Care.
[60] S Greenfield,et al. Variations in resource utilization among medical specialties and systems of care. Results from the medical outcomes study. , 1992, JAMA.
[61] M. Weinstein,et al. Economics of elective coronary revascularization. Comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting and bypass surgery. , 1993, Journal of the American College of Cardiology.
[62] S. Normand,et al. Does prospective payment reduce inpatient length of stay? , 2002, Health economics.
[63] John Nixon,et al. Can economic evaluations be made more transferable? , 2005, The European Journal of Health Economics.
[64] M. Drummond,et al. A Multinational Economic Evaluation of rhDNase in the Treatment of Cystic Fibrosis , 1996, International Journal of Technology Assessment in Health Care.
[65] M. Kretzschmar,et al. Comparative model-based analysis of screening programs for Chlamydia trachomatis infections. , 2001, American journal of epidemiology.
[66] John Urquhart,et al. Pharmacoeconomic Consequences of Variable Patient Compliance With Prescribed Drug Regimens , 1999, PharmacoEconomics.
[67] T Philip,et al. Analysis of the eligibility of published economic evaluations for transfer to a given health care system. Methodological approach and application to the French health care system. , 1999, Health policy.
[68] 農林水産奨励会農林水産政策情報センター,et al. The green book : appraisal and evaluation in central government , 2003 .
[69] Jeffrey A. Alexander,et al. Managed care and technical efficiency in outpatient substance abuse treatment units , 1998, The Journal of Behavioral Health Services & Research.
[70] P. Beutels,et al. Economic Evaluation of Vaccination , 2012, PharmacoEconomics.
[71] Alain C Enthoven,et al. Should operations be regionalized? The empirical relation between surgical volume and mortality. 1979. , 1979, Clinical orthopaedics and related research.
[72] E. Nord,et al. EuroQol: health-related quality of life measurement. Valuations of health states by the general public in Norway. , 1991, Health policy.
[73] Banz,et al. Cost-Effectiveness of Palmaz-Schatzª Stenting in Patients with Coronary Artery Disease in The Netherlands. , 1997, The Journal of invasive cardiology.
[74] S. Yusuf,et al. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation , 1998, The Lancet.
[75] Harold S. Luft,et al. Association of volume with outcome of coronary artery bypass graft surgery —scheduled vs nonscheduled operations , 1987, JAMA.
[76] M A Koopmanschap,et al. The friction cost method for measuring indirect costs of disease. , 1995, Journal of health economics.
[77] W. Manning,et al. Moral Hazard and Consumer Incentives in Health Care , 2000 .
[78] H. Luft,et al. The volume-outcome relationship: practice-makes-perfect or selective-referral patterns? , 1987, Health services research.
[79] H. Luft. The Relation Between Surgical Volume and Mortality: An Exploration of Causal Factors and Alternative Models , 1980, Medical care.
[80] S Bryan,et al. Extrapolation of Cost-Effectiveness Information to Local Settings , 1998, Journal of health services research & policy.
[81] R. Baltussen,et al. Real World Designs in Economic Evaluation , 1999, PharmacoEconomics.
[82] P E Fine,et al. Herd immunity: history, theory, practice. , 1993, Epidemiologic reviews.
[83] F. Antoñanzas. Transferability of Economic Evaluation Results , 2012, PharmacoEconomics.
[84] R Axelsson,et al. Financial incentives in health care. The impact of performance-based reimbursement. , 2001, Health policy.
[85] N. Powe,et al. Methodological Hurdles in Conducting Pharmacoeconomic Analyses , 1999, PharmacoEconomics.
[86] Taghreed Adam,et al. COST-EFFECTIVENESS ANALYSIS: CAN WE REDUCE VARIABILITY IN COSTING METHODS? , 2003, International Journal of Technology Assessment in Health Care.
[87] H. D. de Koning,et al. How cost-effective is breast cancer screening in different EC countries? , 1993, European journal of cancer.
[88] Diane O. Dunet,et al. Variation in Average Costs among Federally Sponsored State-Organized Cancer Detection Programs: Economies of Scale? , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.
[89] G. Tognoni,et al. Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease. , 1996, Archives of internal medicine.
[90] S Greenfield,et al. Variations in resource utilization among medical specialties and systems of care. , 1995, Annual review of public health.
[91] H. Krumholz,et al. In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty. Results from a randomized clinical trial. Stent Restenosis Study Investigators. , 1995, Circulation.
[92] J C Jager,et al. Cost-effectiveness of screening programs for Chlamydia trachomatis: a population-based dynamic approach. , 2000, Sexually transmitted diseases.
[93] N. Black,et al. Outcome of Total Hip Replacement in Japan and England: Comparison of Two Retrospective Cohorts , 1998, International Journal of Technology Assessment in Health Care.
[94] D. Revicki,et al. Pharmacoeconomic Evaluation in the Real World , 1999, PharmacoEconomics.
[95] M. Gold. Cost-effectiveness in health and medicine , 2016 .